These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34169200)

  • 1. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
    Barbour T; Scully M; Ariceta G; Cataland S; Garlo K; Heyne N; Luque Y; Menne J; Miyakawa Y; Yoon SS; Kavanagh D;
    Kidney Int Rep; 2021 Jun; 6(6):1603-1613. PubMed ID: 34169200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.
    Gäckler A; Schönermarck U; Dobronravov V; La Manna G; Denker A; Liu P; Vinogradova M; Yoon SS; Praga M
    BMC Nephrol; 2021 Jan; 22(1):5. PubMed ID: 33407224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.
    Dixon BP; Kavanagh D; Aris ADM; Adams B; Kang HG; Wang E; Garlo K; Ogawa M; Amancha P; Chakravarty S; Heyne N; Kim SH; Cataland S; Yoon SS; Miyakawa Y; Luque Y; Muff-Luett M; Tanaka K; Greenbaum LA
    Kidney Med; 2024 Aug; 6(8):100855. PubMed ID: 39105067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
    Ariceta G; Dixon BP; Kim SH; Kapur G; Mauch T; Ortiz S; Vallee M; Denker AE; Kang HG; Greenbaum LA;
    Kidney Int; 2021 Jul; 100(1):225-237. PubMed ID: 33307104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
    Rondeau E; Scully M; Ariceta G; Barbour T; Cataland S; Heyne N; Miyakawa Y; Ortiz S; Swenson E; Vallee M; Yoon SS; Kavanagh D; Haller H;
    Kidney Int; 2020 Jun; 97(6):1287-1296. PubMed ID: 32299680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.
    Tanaka K; Adams B; Aris AM; Fujita N; Ogawa M; Ortiz S; Vallee M; Greenbaum LA
    Pediatr Nephrol; 2021 Apr; 36(4):889-898. PubMed ID: 33048203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS- real-world data.
    Schönfelder K; Kühne L; Schulte-Kemna L; Kaufeld J; Rohn H; Kribben A; Schröppel B; Brinkkötter PT; Gäckler A
    BMC Nephrol; 2024 Jun; 25(1):202. PubMed ID: 38898427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.
    Cammett TJ; Garlo K; Millman EE; Rice K; Toste CM; Faas SJ
    Mol Diagn Ther; 2023 Jan; 27(1):61-74. PubMed ID: 36329366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Ariceta G
    Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy-Associated Atypical Hemolytic Uremic Syndrome Successfully Treated with Ravulizumab: A Case Report.
    Miyazaki Y; Fukuda M; Hirayu N; Nabeta M; Takasu O
    Cureus; 2024 Feb; 16(2):e54207. PubMed ID: 38496102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab.
    Schaefer F; Al-Dakkak I; Anokhina K; Cohen D; Greenbaum LA; Ariceta G
    Kidney Int Rep; 2024 Sep; 9(9):2648-2656. PubMed ID: 39291212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study.
    Laber DA; Patel PC; Logothetis CN; Patel AK; Jaglal M; Haider M; Visweshwar N; Rajasekaran-Rathnakumar G; Eatrides J
    Eur J Haematol; 2024 Mar; 112(3):450-457. PubMed ID: 37984551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement-Mediated Thrombotic Microangiopathy in Pregnancy: An Educational Case Report.
    Bruno V; Barth D; Jauhal A
    Can J Kidney Health Dis; 2023; 10():20543581231209009. PubMed ID: 37942411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.
    Schrezenmeier H; Kulasekararaj A; Mitchell L; Sicre de Fontbrune F; Devos T; Okamoto S; Wells R; Rottinghaus ST; Liu P; Ortiz S; Lee JW; Socié G
    Ther Adv Hematol; 2020; 11():2040620720966137. PubMed ID: 33178408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab.
    Chung C
    Ann Pharmacother; 2021 Mar; 55(3):330-343. PubMed ID: 32715723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of the Terminal Complement Cascade Using Ravulizumab in a Pediatric Patient With Anti-complement Factor H Autoantibody-Associated aHUS: A Case Report and Literature Review.
    Wu X; Szarzanowicz A; Garba A; Schaefer B; Waz WR
    Cureus; 2021 Nov; 13(11):e19476. PubMed ID: 34912617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
    N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.